Drug Profile
Crofelemer - Napo Pharmaceuticals
Alternative Names: CRO-HIV; CRO-IBS; CRO-ID; CRO-PED; Fulyzaq; Mytesi; Provir; SP 303; TRN-002- Napo Pharmaceuticals; VirendLatest Information Update: 26 Apr 2024
Price :
$50
*
At a glance
- Originator Shaman Pharmaceuticals
- Developer Napo Pharmaceuticals; Puma Biotechnology; Salix Pharmaceuticals; Shaman Pharmaceuticals; University of California at San Francisco
- Class Antidiarrhoeals; Biopolymers; Chromans; Flavonoids; Irritable bowel syndrome therapies; Phytotherapies; Small molecules
- Mechanism of Action Chloride channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Diarrhoea
- Phase II Irritable bowel syndrome; Short bowel syndrome
- No development reported Inflammatory bowel diseases
- Discontinued Herpes simplex virus infections; Influenza virus infections
Most Recent Events
- 25 Apr 2024 Jaguar plans clinical trial for Diarrhoea in 2022
- 31 Dec 2023 US FDA accepts IND for Crofelemer for Diarrhoea (PO, Powder) for review
- 05 Dec 2023 Napo Pharmaceuticals completes enrolment in its phase III OnTARGET trial for Diarrhoea (Prevention, Chemotherapy-induced) in Taiwan, Serbia, Georgia, Argentina, USA (NCT04538625)